JP2022501074A5 - - Google Patents
Info
- Publication number
- JP2022501074A5 JP2022501074A5 JP2021542089A JP2021542089A JP2022501074A5 JP 2022501074 A5 JP2022501074 A5 JP 2022501074A5 JP 2021542089 A JP2021542089 A JP 2021542089A JP 2021542089 A JP2021542089 A JP 2021542089A JP 2022501074 A5 JP2022501074 A5 JP 2022501074A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- γδt
- sequence
- seq
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025085673A JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739822P | 2018-10-01 | 2018-10-01 | |
| US62/739,822 | 2018-10-01 | ||
| PCT/US2019/054132 WO2020072536A1 (en) | 2018-10-01 | 2019-10-01 | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025085673A Division JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501074A JP2022501074A (ja) | 2022-01-06 |
| JP2022501074A5 true JP2022501074A5 (enExample) | 2022-10-12 |
| JP7687952B2 JP7687952B2 (ja) | 2025-06-03 |
Family
ID=68393055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542089A Active JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
| JP2025085673A Pending JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025085673A Pending JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12692319B2 (enExample) |
| EP (1) | EP3860645A1 (enExample) |
| JP (2) | JP7687952B2 (enExample) |
| CN (1) | CN113056283A (enExample) |
| BR (1) | BR112021006182A2 (enExample) |
| CA (1) | CA3115139A1 (enExample) |
| EA (1) | EA202190926A1 (enExample) |
| IL (1) | IL281922A (enExample) |
| MX (1) | MX2021003745A (enExample) |
| SG (1) | SG11202103235PA (enExample) |
| WO (1) | WO2020072536A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| BR112021006182A2 (pt) * | 2018-10-01 | 2021-06-29 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| BR112022001194A2 (pt) * | 2019-07-24 | 2022-06-07 | Regeneron Pharma | Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN113667640B (zh) * | 2021-08-27 | 2022-09-02 | 广州百暨基因科技有限公司 | CAR-γδT细胞的制备方法 |
| AU2022401701A1 (en) * | 2021-12-05 | 2024-06-20 | Adicet Therapeutics, Inc. | Treatment of b cell malignancies |
| CN116574194A (zh) * | 2022-06-02 | 2023-08-11 | 深圳普瑞金生物药业股份有限公司 | 嵌合抗原受体及其用途 |
| PE20260290A1 (es) | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| WO2025011459A1 (en) * | 2023-07-07 | 2025-01-16 | Nanjing Legend Biotech Co., Ltd. | Proteins and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100944575B1 (ko) * | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| SG188175A1 (en) * | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| PT1809321E (pt) | 2004-10-08 | 2012-05-17 | Us Gov Health & Human Serv | Imunoterapia adotiva com sobrevivência aumentada de linfócitos |
| EP1891113A2 (en) * | 2005-06-02 | 2008-02-27 | AstraZeneca AB | Antibodies directed to cd20 and uses thereof |
| JP5588865B2 (ja) | 2007-07-31 | 2014-09-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｃｄ２０に対するヒト抗体及びその使用方法 |
| WO2010042490A1 (en) | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2710123B1 (en) | 2011-05-19 | 2017-07-12 | Instituto de Medicina Molecular | Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof |
| EP3919079A1 (en) * | 2012-09-07 | 2021-12-08 | Genentech, Inc. | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
| CN104087607B (zh) | 2013-04-01 | 2017-06-20 | 科济生物医药（上海）有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
| US9907820B2 (en) | 2013-10-25 | 2018-03-06 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta T cells for immunotherapy |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| WO2016005752A1 (en) | 2014-07-09 | 2016-01-14 | Tc Biopharm Ltd | Gamma delta t cells and uses thereof |
| AU2015292744C1 (en) * | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| WO2016034666A1 (en) * | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| RU2756247C2 (ru) * | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| CA2977106A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| JP6799895B2 (ja) | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． | ＴＣＲγδ＋Ｔ細胞の生産方法 |
| CA3172801A1 (en) * | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| WO2017083750A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| EP4086285A1 (en) | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| CN118421557A (zh) | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| CN107523545A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| CN110035768A (zh) | 2016-07-26 | 2019-07-19 | 泰莎治疗私人有限公司 | 嵌合抗原受体 |
| MX2019005277A (es) | 2016-11-04 | 2019-09-27 | Bluebird Bio Inc | Composiciones de celulas t con car anti-bcma. |
| CA3042613A1 (en) * | 2016-11-11 | 2018-05-17 | Autolus Limited | Chimeric antigen receptor |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| TWI831365B (zh) | 2017-01-10 | 2024-02-01 | 國立大學法人山口大學 | 抗ｇｐｃ３抗體 |
| EP3572427B1 (en) | 2017-01-23 | 2025-06-25 | CRAGE medical Co., Limited | Bcma-targeting antibody and use thereof |
| GB201701332D0 (en) | 2017-01-26 | 2017-03-15 | Tc Biopharm Ltd | Immune cells with modified metabolism and their use thereof |
| MY200528A (en) * | 2017-02-08 | 2023-12-30 | Agency Science Tech & Res | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same |
| GB2562774A (en) | 2017-05-25 | 2018-11-28 | Mcdonald Michael | Genetic construct |
| KR20200021074A (ko) | 2017-06-14 | 2020-02-27 | 아디셋 바이오, 인크. | Hla 제한된 방식으로 hla-a2/tyrd를 결합할 수 있는 항체 및 이의 용도 |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| WO2019210293A1 (en) * | 2018-04-27 | 2019-10-31 | Baylor College Of Medicine | Car t cells with one or more interleukins |
| CN108588023B (zh) | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| WO2020017479A1 (ja) | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ |
| WO2020061048A1 (en) * | 2018-09-17 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
| BR112021006182A2 (pt) * | 2018-10-01 | 2021-06-29 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos |
-
2019
- 2019-10-01 BR BR112021006182-7A patent/BR112021006182A2/pt unknown
- 2019-10-01 CN CN201980070384.5A patent/CN113056283A/zh active Pending
- 2019-10-01 WO PCT/US2019/054132 patent/WO2020072536A1/en not_active Ceased
- 2019-10-01 US US17/281,574 patent/US12692319B2/en active Active
- 2019-10-01 SG SG11202103235PA patent/SG11202103235PA/en unknown
- 2019-10-01 MX MX2021003745A patent/MX2021003745A/es unknown
- 2019-10-01 EA EA202190926A patent/EA202190926A1/ru unknown
- 2019-10-01 CA CA3115139A patent/CA3115139A1/en active Pending
- 2019-10-01 JP JP2021542089A patent/JP7687952B2/ja active Active
- 2019-10-01 EP EP19795699.8A patent/EP3860645A1/en active Pending
-
2021
- 2021-03-31 IL IL281922A patent/IL281922A/en unknown
-
2025
- 2025-05-22 JP JP2025085673A patent/JP2025134707A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7336457B2 (ja) | 抗体Ｆｃ領域を主鎖として用いた融合タンパク質二量体及びその使用 | |
| JP7111855B2 (ja) | ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 | |
| CN111655716B (zh) | 基于il-15的与il-7和il-21的融合体 | |
| JP6968389B2 (ja) | Ｂｃｍａに結合するキメラ抗原受容体（ｃａｒ）及びその応用 | |
| CN106536563B (zh) | 嵌合抗原受体 | |
| JP2022066290A5 (enExample) | ||
| TWI646107B (zh) | Ｂｃｍａ及ｃｄ３之結合分子 | |
| JP2025134707A5 (enExample) | ||
| RU2018147423A (ru) | Анти-PD-L1 и IL-2 цитокины | |
| JP2018508215A (ja) | Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ） | |
| CN111386125A (zh) | 多肽 | |
| CN111514292A (zh) | 抗人白介素4受体α单克隆抗体的制药用途 | |
| WO2014207064A1 (en) | Bispecific molecules capable of specifically binding to both ctla-4 and cd40 | |
| TW202221021A (zh) | 改良之抗原結合受體 | |
| CN115232209A (zh) | 靶向gprc5d的抗体及其用途 | |
| JP2022513321A5 (enExample) | ||
| JP2024525492A5 (enExample) | ||
| JP2022501074A (ja) | 血液腫瘍を治療するための遺伝子操作しているγδ−Ｔ細胞及び遺伝子操作していないγδ−Ｔ細胞に関する組成物及び方法 | |
| JP7812549B2 (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| TW201841944A (zh) | 4-1bbl變異體及包含其之融合蛋白 | |
| JP2022532249A (ja) | インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法 | |
| JP2024536840A (ja) | Ｉｌ－２バリアント及びその融合タンパク質 | |
| KR20240046224A (ko) | 이중특이성 항체 및 그 용도 | |
| CN118302443A (zh) | 改善的抗原结合受体 | |
| JP2023553049A (ja) | Ｃｄ１９＋、ｃｄ２０＋、若しくはｃｄ２２＋腫瘍又はｂ細胞由来の自己免疫疾患を治療するためのｃａｒ ｔ細胞 |